The Clinical Significance Of The Count Of Tumor Cells And The Expression Of CD133 And CK In Malignant Pleural Effusion In NSCLC

Ami:To explore the clinical significance of the count of tumor cells and the expression of CD133 and CK in malignant pleural effusion in non-small cell lung cancer.Methods:53 cases of newly diagnosed patients with pathologically confirmed non-small cell lung cancer complicated with malignant pleural effusion were selected as subjects,and collect 10 ml of pleural effusion before patients receive chemotherapy.We use human pleural effusion tumor cell subtraction enrichment kit to enrichment of tumor cells in pleural effusion,and then we use immunostaining-fluorescence in situ hybridization tumor cell detection kit,human solid tumor stem cell CD133 kit,cytokeratin immunofluorescence staining kit for chromosome identification to detect the enriched tumor cells and the expression of CD 133 and CK.Using SPSS software to process experimental data to analyzed the correlation between tumor cells,the expression of CD 133 and CK and clinical data(sex,age,pathological type),metastasis,prognosis and curative effect.Results:1.Among 53 patients with non-small cell lung cancer and pleural effusion,the number of male pleural fluid tumor cells was(5?584000)/10mL,and the median number of cells was 5500/10mL,the number of female pleural fluid tumor cells was(0?190000)/10mL,and the median number of cells was 4164/lOmL.The difference was not statistically significant(P=0.481).The number of pleural fluid tumor cells in patients younger than 60 years old was(46?190000)/10mL.the median number of cells was 3269/10mL?and the number of pleural fluid tumor cells aged over 60 years old was(0?584000)/10mL,the median number of cells was 7800/10mL,the difference was not statistically significant(P=0.557);The number of pleural fluid tumor cells in lung adenocarcinoma was(5?584000)/10mL.the median number of cells is 5000/10mL.and the number of pleural fluid tumor cells in lung squamous cell carcinoma was(0?170000)/10mL,and the number of median cells is one.5982/1 OmL,the difference was not statistically significant(P=0.960);The number of pleural fluid tumor cells in patients with or without regional lymph node metastasis was(5?100000)/10mL,and the median number of cells was 1500/1 OmL,with the number of pleural fluid tumor cells in patients with lung or distant lymph nodes or other organ metastases was(0?584000)/10mL,the median number of cells was 12217/10mL,the difference was statistically significant(P=0.016),and the number of pleural fluid tumor cells in patients with intrapulmonary or distant lymph nodes or other organ metastasis was more those with or without regional lymph node metastasis;The number of pleural fluid tumor cells in PR patients was(0?584000)/10mL,and the median number of cells was 623.5/10mL.The number of pleural fluid tumor cells in SD patients was(200?100000)/10mL,and the median number of cells was 2140/10mL.The number of pleural fluid tumor cells in 1 OmL patients with PD was(1500?398000)/10mL.and the median number of cells was 17370/10mL.The difference was statistically significant(P=0.006).The number of tumor cells in pleural effusion of PR patients was the lowest.The number of tumor cells in the pleural effusion was the highest,and the number of tumor cells in the pleural effusion of SD patients was between them2.In 35 patients with non-small cell lung cancer and pleural effusion detected CD 133+tumor cells,the number of male pleural fluid CD 133+tumor cells was(5?12750)/10mL,and the median number of cells was 260/10mL,the number of female pleural fluid CD133+tumor cells was(13-22680)/10mL,and the median number of cells was 24/10mL.The difference was not statistically significant(P=0.352).The number of pleural fluid CD 133+tumor cells in patients younger than 60 years old was(18?2065)/10mL.the median number of cells was 207.5/10mL,and the number of pleural fluid CD133+tumor cells aged over 60 years old was(2?22680)/10mL,the median number of cells was 72/10mL,the difference was not statistically significant(P=0.630);The number of pleural fluid CD133+tumor cells in lung adenocarcinoma is(5?4260)/10mL,the median number of cells is 79.5/10mL,and the number of pleural fluid CD133+tumor cells in lung squamous cell carcinoma is(13?22680)/10mL,and the number of median cells is one.1000/1 OmL,the difference was not statistically significant(P=0.114);The number of pleural fluid CD133+tumor cells in patients with or without regional lymph node metastasis was(5?4260)/10mL,and the median number of cells was 21/10mL,with the number of pleural fluid CD133+tumor cells in patients with lung or distant lymph nodes or other organ metastases was(16?22680)/10mL,the median number of cells was 515/10mL,the difference was statistically significant(P=0.002),and the number of pleural fluid CD 133+tumor cells in patients with intrapulmonary or distant lymph nodes or other organ metastasis was more those with or without regional lymph node metastasis;The number of pleural fluid CD133+tumor cells in PR patients was(5?130)/10mL,and the median number of cells was 12/10mL.The number of pleural fluid CD133+tumor cells in SD patients was(15?1310)/10mL,and the median number of cells was 35/1 OmL.The number of pleural fluid CD 133+tumor cells in lOmL patients with PD was(280-22680)/10mL,and the median number of cells was 1324/10mL.The difference was statistically significant(P=<0.001).The number of CD133+tumor cells in pleural effusion of PR patients was the lowest.The number of CD133+tumor cells in the pleural effusion was the highest,and the number of CD 133+tumor cells in the pleural effusion of SD patients was between them3.The progression free survival(PFS)of patients with CD133+tumor cells was(1.5-8)months,with a median of 4 months.The progression free survival(PFS)of patients without CD 133+tumor cells was(2-9)months,with a median of 6 months,the difference was statistically significant(P<0.001)?the progression free survival(PFS)of patients with CD133+tumor cells was shorter than those without CD133+tumor cells.The Overall survival(OS)of patients with CD133+tumor cells was(2.5-9)months,with a median of 5.5 months.The Overall survival(OS)of patients without CD 133+tumor cells was(2.5?10),with a median of 8 months,the difference was statistically significant(P<0.001).and the overall survival(OS)of patients with CD 133+tumor cells was shorter than those without CD133+tumor cells4.The progression free survival(PFS)of patients with CD133+CK+tumor cells was(4.5-8)months,with a median of 5.5 months.The progression free survival(PFS)of patients with CD 133+CK-tumor cells was(1.5?7)months,with a median of 4 months.the difference was statistically significant(P=0.008),the progression free survival(PFS)of patients with CD133+CK+tumor cells was longer than those with CD133+CK-tumor cells.The Overall survival(OS)of patients with CD133+CK+tumor cells was(5.5-9)months,with a median of 6.5 months.The Overall survival(OS)of patients with CD133+CK-tumor cells was(2.5-8),with a median of 5 months.the difference was statistically significant(P<0.001).and the overall survival(OS)of patients with CD133+CK+tumor cells was longer than those with CD133+CK-tumor cellsConclusion:1.The number of tumor cells and CD 133+tumor cells in malignant pleural effusion in patients with non-small cell lung cancer were negatively correlated with the metastasis range and chemotherapy efficacy,and were not correlated with gender,age and pathological type2.The expression of CD133 and CK is associated with the prognosis of non-small cell lung cancer.CD133+CK-tumor cells predict a worse prognosis than CD133+tumor cells and CD 133+CK+tumor cells.